Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (GB:0JXI)
LSE:0JXI
RESEARCH TOOLSreports
Holding GB:0JXI?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$4.51Last Year’s EPS
-$5.68Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: 44.61%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong and promising launch of Rezdiffra with significant achievements in sales, coverage, and prescriber penetration. However, increased operational expenses and future uncertainties in gross-to-net adjustments present challenges. Overall, the sentiment is optimistic with a cautious outlook on future financial dynamics.Company Guidance
During Madrigal Pharmaceuticals' third-quarter 2024 earnings call, the company reported $62 million in net sales for Rezdiffra, a NASH treatment, with over 6,800 patients on the drug, reflecting strong demand. The company achieved coverage for more than 80% of commercial lives, surpassing its year-end goal a quarter early. Rezdiffra's prescription rate doubled among top prescribers, contributing to the launch's success. The company anticipates further growth with the potential EMA approval for a European launch in the second half of 2025 and is preparing for Medicare coverage starting January 2025. Additionally, Madrigal completed enrollment for its MAESTRO-NASH OUTCOMES trial, aiming to position Rezdiffra as a leading therapy for NASH.Strong U.S. Rezdiffra Launch
Madrigal Pharmaceuticals reported $62 million in net sales for Rezdiffra in the third quarter, with more than 6,800 patients on the medication, indicating a strong launch phase.
Successful Coverage Milestone
Secured coverage for over 80% of commercial lives a quarter ahead of schedule, with greater than 95% of covered lives accepting non-invasive tests, bypassing the need for biopsies.
Progress in Prescriber Penetration
Around 40% of top target prescribers are now prescribing Rezdiffra, doubling from the previous quarter, indicating expanding breadth and depth in the prescriber base.
Cirrhosis OUTCOMES Trial Enrollment Completion
Completed enrollment for the MAESTRO-NASH OUTCOMES trial, marking a significant milestone towards addressing NASH cirrhosis, with potential regulatory approval making Rezdiffra the first therapy for compensated NASH cirrhosis.
Positive Financial Position
Madrigal maintains a strong financial position with $1 billion in cash, cash equivalents, and marketable securities to support ongoing and future initiatives.
---
GB:0JXI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0JXI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $217.03 | $262.48 | +20.94% |
| Aug 07, 2024 | $269.67 | $232.47 | -13.80% |
| May 07, 2024 | $226.68 | $219.00 | -3.39% |
| Feb 28, 2024 | $242.17 | $251.47 | +3.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Madrigal Pharmaceuticals Inc (GB:0JXI) report earnings?
Madrigal Pharmaceuticals Inc (GB:0JXI) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Madrigal Pharmaceuticals Inc (GB:0JXI) earnings time?
Madrigal Pharmaceuticals Inc (GB:0JXI) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Madrigal Pharmaceuticals Inc stock?
The P/E ratio of Madrigal Pharmaceuticals is N/A.
What is GB:0JXI EPS forecast?
GB:0JXI EPS forecast for the fiscal quarter 2024 (Q4) is -$4.51.
---